Live Breaking News & Updates on Checkpoint Inhibitor Single Agent Study

Stay updated with breaking news from Checkpoint inhibitor single agent study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

SELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer

- Median Overall Survival for GPS Combination was 18.4 Months Compared to 13.8 months in a Checkpoint Inhibitor Single Agent Study in a Similar Patient Population Treated with Checkpoint Inhibitor. | November 10, 2022 ....

United States , Angelos Stergiou , Michaela Fawcett , Bruno Bastos , Allison Soss , Raquel Cona , Herbert Wertheim College Of Medicine , Company Wilms , Genfleet Therapeutics Shanghai Inc , Merck Co Inc , Strategic Communications , Life Sciences Group Inc , Merck Sharp Dohme , Miami Cancer Institute , Memorial Sloan Kettering Cancer Center , Globenewswire Inc , Overall Survival , Checkpoint Inhibitor Single Agent Study , Similar Patient Population Treated , Checkpoint Inhibitor Alone , Progression Free Survival , Eight Weeks , Increased Disease Control Rate , Patients Harboring Tumors , Clinical Trial Data , Medical Conference ,